Record-Breaking Obesity Certifications; 365-Day CGM Data; Med Spa Mounjaro Lawsuits

A record-breaking number of U.S. physicians applied to be certified in obesity medicine this year, according to the American Board of Obesity Medicine.

Two Roche distributors are under investigation in Pakistan after 12 patients with diabetes went blind following an injection of bevacizumab (Avastin), a cancer drug used off-label for diabetes-related eye conditions. (Reuters)

The American Thyroid Association released a new statement guiding clinicians on safe ablation techniques for benign thyroid nodules. (Thyroid)

The Eversense implantable continuous glucose monitor (CGM) proved safe and accurate with 365 days of wear, Senseonics Holdings announced; the company plans to submit the data to the FDA for approval. Currently no CGM system is approved for year-long use.

In a press release, Eli Lilly explained why it sued medical spas, wellness centers, and compounding pharmacies for selling products claiming to contain the type 2 diabetes drug tirzepatide (Mounjaro), which may be approved for weight loss this year.

Women exposed to a slew of endocrine-disrupting chemicals, like phenols and parabens, had higher odds of melanoma and ovarian cancer. (Journal of Exposure Science & Environmental Epidemiology)

SGLT2 inhibitors and GLP-1 receptor agonists may be less beneficial for Black patients with type 2 diabetes when it comes to cardiovascular and kidney outcomes. (Journal of the Royal Society of Medicine)

Even in states where gender-affirming care for minors is legal, some providers are curbing the treatments out of liability concerns. (AP)

In fact, more than half of pediatric endocrinologists providing gender-affirming care surveyed said they were concerned about the risk of legal action against them. (Journal of the Endocrine Society)

Please enable JavaScript to view the

comments powered by Disqus.